Eli Lilly retatrutide Phase 3 trials show major weight loss

Statements (2)

1. ● Neutral

   Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon

   arstechnica.comSep 29, 2026 22:30 UTC
2. ▲ Bullish

   Eli Lilly's triple agonist retatrutide helped patients with obesity and type 2 diabetes lose up to 18.8% of their weight after about a year and a half

   endpoints.newsSep 29, 2026 22:01 UTCHigh importance